+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Living Biological Drugs Market - Global Forecast 2026-2032- Product Image
Living Biological Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Living Biological Drugs Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6153222
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Living Biological Drugs Market is projected to reach USD 418.64 Million in 2026. It is expected to continue growing at a CAGR of 7.73%, reaching USD 652.89 Million by 2032.

Living Biological Drugs: Executive Overview

Living biological drugs use viable cells, tissues, microorganisms, or other biological systems as active therapeutic components. Their development differs from conventional medicines because product performance depends on biological behavior, manufacturing conditions, handling, and patient-specific factors. The field includes cell-based therapies, tissue-engineered products, live biotherapeutics, and related modalities. Progress is shaped by advances in molecular biology, gene editing, biomaterials, cryopreservation, quality control, and specialized clinical-trial design.

Manufacturing and Regulatory Shifts Reshape Development

The landscape is moving from research-led proof of concept toward integrated development systems that connect biological characterization, process control, logistics, clinical evidence, and long-term follow-up. Manufacturing remains a central differentiator: living products may require controlled environments, rapid processing, validated storage, and chain-of-identity or chain-of-custody systems. Regulators are also emphasizing product comparability, potency assays, contamination control, donor or source qualification, and evidence of durability. These requirements encourage earlier collaboration among developers, manufacturers, hospitals, logistics providers, and regulators.

Artificial Intelligence Strengthens Discovery, Manufacturing, and Care Pathways

Artificial intelligence can support living biological drugs by analyzing multi-omic data, identifying response biomarkers, optimizing culture conditions, detecting manufacturing deviations, and improving clinical-trial recruitment. Machine-learning tools may also help match patients with suitable products and monitor treatment outcomes over time. However, biological variability, limited standardized datasets, explainability requirements, privacy obligations, and the need for prospective validation constrain deployment. The most credible near-term value is likely to come from decision support and process analytics that remain subject to laboratory, clinical, and regulatory controls.

Regional Insights: Capabilities and Access Develop Unevenly

North America combines advanced biomedical research, specialized manufacturing, and established regulatory pathways, while Latin America is strengthening clinical-research and biomanufacturing capabilities amid access and infrastructure constraints. Europe benefits from coordinated scientific networks and sophisticated regulatory institutions, though cross-border reimbursement and manufacturing alignment remain important considerations. The Middle East is investing in healthcare modernization, research capacity, and specialized treatment infrastructure. Africa faces substantial needs in financing, cold-chain systems, skilled personnel, and technology transfer. Asia-Pacific spans highly advanced ecosystems in countries such as Japan, South Korea, Australia, and China alongside rapidly developing capabilities elsewhere, making regional partnerships and localized infrastructure particularly relevant.

Group Insights: Alliances Shape Standards, Capacity, and Access

ASEAN countries are pursuing stronger biomedical collaboration and regional health capacity while continuing to address differences in regulation, infrastructure, and reimbursement. BRICS members represent diverse scientific and manufacturing environments, with opportunities for technology transfer tempered by varying regulatory systems and healthcare resources. The European Union benefits from shared policy structures and cross-border research mechanisms, but implementation across national health systems can remain complex. G7 economies provide substantial research, clinical, and regulatory expertise. GCC states are building advanced healthcare and life-science capabilities, while NATO members offer extensive translational networks and logistics expertise, although these groupings are not uniform in health-policy priorities.

Country Insights: Distinct Strengths and Development Priorities

Australia combines strong clinical research with a geographically dispersed care system. Brazil and Mexico are expanding biotechnology and clinical capabilities while facing access, infrastructure, and regulatory implementation challenges. Canada benefits from research depth and public healthcare coordination. China is developing large-scale biomedical infrastructure and domestic manufacturing. France, Germany, Italy, Spain, and the United Kingdom contribute substantial research, hospital, regulatory, and manufacturing expertise, with reimbursement and cross-border coordination remaining important. India offers a broad scientific and manufacturing base alongside major affordability and healthcare-access considerations. Japan and South Korea have advanced biomedical industries and rigorous regulatory environments. Russia retains scientific capabilities but operates within significant collaboration and supply constraints. The United States has extensive translational research, specialized manufacturing, and clinical infrastructure, while affordability and care delivery remain central concerns.

Action Priorities for Leaders in Living Biological Drugs

Industry leaders should establish development plans that integrate product characterization, manufacturing controls, clinical evidence, logistics, and long-term monitoring from the outset. Investment should prioritize robust potency and identity assays, scalable closed-system processing, contamination prevention, validated cryopreservation, and resilient supply networks. Organizations should engage regulators and health systems early, define evidence requirements for durability and real-world performance, and build partnerships that improve treatment access. Artificial intelligence initiatives should begin with well-governed, high-quality datasets, transparent validation, cybersecurity safeguards, and clearly assigned human accountability. Regional strategies should reflect local infrastructure, reimbursement, workforce, and technology-transfer conditions rather than assume a single global operating model.

Research Methodology: Evidence-Led Assessment of a Complex Modality

This executive summary uses a structured review of the living biological drugs domain, organized around product characteristics, enabling technologies, manufacturing, regulation, clinical translation, healthcare delivery, regional conditions, and policy considerations. Insights are synthesized qualitatively from established scientific and regulatory concepts rather than from market estimates or projections. Geographic comparisons consider research capacity, biomanufacturing infrastructure, regulatory maturity, logistics, healthcare access, and partnership potential. Artificial-intelligence observations distinguish demonstrated analytical applications from areas requiring further validation. Because the field evolves rapidly, conclusions should be refreshed as standards, clinical evidence, reimbursement policies, and manufacturing practices change.

Conclusion: Scaling Living Therapies Requires Integrated Execution

Living biological drugs offer the potential to address diseases and biological mechanisms that are difficult to treat with conventional medicines, but their complexity extends across discovery, manufacturing, delivery, monitoring, and reimbursement. Durable progress will depend on reliable biological characterization, reproducible production, fit-for-purpose regulation, specialized care pathways, and equitable access. Regional and national conditions will determine how quickly capabilities translate into patient benefit. Leaders that combine scientific rigor with operational resilience, responsible artificial intelligence, and early stakeholder collaboration will be best positioned to advance the field sustainably.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Living Biological Drugs Market, by Product Type
7.1. Introduction
7.2. Cell Therapy
7.2.1. CAR-T Therapy
7.2.2. Dendritic Cell Therapy
7.2.3. Natural Killer Cell Therapy
7.2.4. Stem Cell Therapy
7.2.4.1. Hematopoietic
7.2.4.2. Mesenchymal
7.3. Gene Therapy
7.3.1. Nonviral Vector Based
7.3.2. Viral Vector Based
7.4. Tissue Engineered Products
7.4.1. Scaffold Based
7.4.2. Scaffold Free
8. Living Biological Drugs Market, by Source
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
9. Living Biological Drugs Market, by Delivery Mode
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Subcutaneous
10. Living Biological Drugs Market, by Application
10.1. Introduction
10.2. Cardiovascular
10.3. Immunology
10.4. Neurology
10.5. Oncology
10.5.1. Hematological Malignancies
10.5.2. Solid Tumors
10.6. Ophthalmology
11. Living Biological Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.5. Specialty Clinic
12. Living Biological Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Living Biological Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Living Biological Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. bluebird bio, Inc.
16.2. Bristol-Myers Squibb Company
16.3. F. Hoffmann-La Roche Ltd.
16.4. Gilead Sciences, Inc.
16.5. Johnson & Johnson
16.6. Legend Biotech Corporation
16.7. Novartis AG
16.8. Pfizer Inc.
16.9. Samsung Biologics Co.,Ltd.
16.10. Sanofi S.A.
16.11. Takeda Pharmaceutical Company Limited
16.12. Thermo Fisher Scientific Inc.
16.13. Vertex Pharmaceuticals, Inc.
16.14. WuXi Biologics Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Living Biological Drugs Market, Years Considered for the Study
FIGURE 2. Global Living Biological Drugs Market, Research Design
FIGURE 3. Global Living Biological Drugs Market, Research Framework
FIGURE 4. Global Living Biological Drugs Market, Data Triangulation
FIGURE 5. Global Living Biological Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Living Biological Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Living Biological Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Living Biological Drugs Market Size, by Source, 2025 vs 2032 (%)
FIGURE 9. Global Living Biological Drugs Market Size, by Source, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Living Biological Drugs Market Size, by Delivery Mode, 2025 vs 2032 (%)
FIGURE 11. Global Living Biological Drugs Market Size, by Delivery Mode, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Living Biological Drugs Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Living Biological Drugs Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Living Biological Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Living Biological Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Living Biological Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Living Biological Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Living Biological Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Living Biological Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Living Biological Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Living Biological Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Living Biological Drugs Market Segmentation & Coverage
TABLE 2. Global Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global CAR-T Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global CAR-T Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global CAR-T Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Dendritic Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Dendritic Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Dendritic Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Natural Killer Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Natural Killer Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Natural Killer Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Stem Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Stem Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Stem Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Hematopoietic Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Hematopoietic Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Hematopoietic Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Mesenchymal Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Mesenchymal Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Mesenchymal Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Nonviral Vector Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Nonviral Vector Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Nonviral Vector Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Viral Vector Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Viral Vector Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Viral Vector Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Tissue Engineered Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Tissue Engineered Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Tissue Engineered Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Scaffold Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Scaffold Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Scaffold Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Scaffold Free Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Scaffold Free Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Scaffold Free Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 44. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 51. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 61. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. North America Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. North America Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 109. North America Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 110. North America Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 111. North America Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 112. North America Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 113. North America Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 114. North America Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 115. North America Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 116. North America Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 117. North America Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. Latin America Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Latin America Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. Latin America Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 121. Latin America Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 122. Latin America Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 123. Latin America Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 124. Latin America Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 125. Latin America Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 126. Latin America Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. Latin America Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 128. Latin America Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Europe Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Europe Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. Europe Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 132. Europe Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 133. Europe Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 134. Europe Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 135. Europe Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 136. Europe Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 137. Europe Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. Europe Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 139. Europe Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Middle East Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Middle East Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. Middle East Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 143. Middle East Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 144. Middle East Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 145. Middle East Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 146. Middle East Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 147. Middle East Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 148. Middle East Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 149. Middle East Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 150. Middle East Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Africa Living Biological Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Africa Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 153. Africa Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 154. Africa Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 155. Africa Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 156. Africa Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 157. Africa Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 158. Africa Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 159. Africa Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 160. Africa Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 161. Africa Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Global Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. ASEAN Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. ASEAN Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. ASEAN Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 166. ASEAN Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 167. ASEAN Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 168. ASEAN Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 169. ASEAN Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 170. ASEAN Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 171. ASEAN Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. ASEAN Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. ASEAN Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. GCC Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. GCC Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 176. GCC Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 177. GCC Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 178. GCC Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 179. GCC Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 180. GCC Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 181. GCC Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 182. GCC Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 183. GCC Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 184. GCC Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. European Union Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. European Union Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. European Union Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 188. European Union Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 189. European Union Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 190. European Union Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 191. European Union Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 192. European Union Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 193. European Union Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. European Union Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 195. European Union Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. BRICS Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. BRICS Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. BRICS Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 199. BRICS Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 200. BRICS Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 201. BRICS Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 202. BRICS Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 203. BRICS Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 204. BRICS Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 205. BRICS Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 206. BRICS Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. G7 Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 208. G7 Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 209. G7 Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 210. G7 Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 211. G7 Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 212. G7 Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 213. G7 Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 214. G7 Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 215. G7 Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 216. G7 Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 217. G7 Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. NATO Living Biological Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. NATO Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. NATO Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 221. NATO Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 222. NATO Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 223. NATO Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 224. NATO Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 225. NATO Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 226. NATO Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 227. NATO Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 228. NATO Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Global Living Biological Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 230. United States Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 231. United States Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 232. United States Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 233. United States Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 234. United States Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 235. United States Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 236. United States Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 237. United States Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 238. United States Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 239. United States Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 240. United States Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Canada Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 242. Canada Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 243. Canada Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 244. Canada Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 245. Canada Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 246. Canada Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 247. Canada Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 248. Canada Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 249. Canada Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. Canada Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 251. Canada Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Mexico Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 253. Mexico Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 254. Mexico Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 255. Mexico Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 256. Mexico Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 257. Mexico Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 258. Mexico Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 259. Mexico Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 260. Mexico Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. Mexico Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 262. Mexico Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Brazil Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 264. Brazil Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 265. Brazil Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 266. Brazil Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 267. Brazil Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 268. Brazil Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 269. Brazil Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 270. Brazil Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 271. Brazil Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 272. Brazil Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 273. Brazil Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. United Kingdom Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 275. United Kingdom Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 276. United Kingdom Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 277. United Kingdom Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 278. United Kingdom Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 279. United Kingdom Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 280. United Kingdom Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 281. United Kingdom Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 282. United Kingdom Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. United Kingdom Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 284. United Kingdom Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 285. Germany Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 286. Germany Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 287. Germany Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 288. Germany Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 289. Germany Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 290. Germany Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 291. Germany Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 292. Germany Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 293. Germany Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 294. Germany Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 295. Germany Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 296. France Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 297. France Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 298. France Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 299. France Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 300. France Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 301. France Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 302. France Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 303. France Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 304. France Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 305. France Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 306. France Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 307. Russia Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 308. Russia Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 309. Russia Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 310. Russia Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 311. Russia Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 312. Russia Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 313. Russia Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 314. Russia Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 315. Russia Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 316. Russia Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 317. Russia Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 318. Italy Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 319. Italy Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 320. Italy Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 321. Italy Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 322. Italy Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 323. Italy Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 324. Italy Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 325. Italy Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 326. Italy Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 327. Italy Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 328. Italy Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 329. Spain Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 330. Spain Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 331. Spain Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 332. Spain Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 333. Spain Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 334. Spain Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 335. Spain Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 336. Spain Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 337. Spain Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 338. Spain Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 339. Spain Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 340. China Living Biological Drugs Market Size, 2017-2032 (USD Million)
TABLE 341. China Living Biological Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 342. China Living Biological Drugs Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 343. China Living Biological Drugs Market Size, by Stem Cell Therapy, 2017-2032 (USD Million)
TABLE 344. China Living Biological Drugs Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 345. China Living Biological Drugs Market Size, by Tissue Engineered Products, 2017-2032 (USD Million)
TABLE 346. China Living Biological Drugs Market Size, by Source, 2017-2032 (USD Million)
TABLE 347. China Living Biological Drugs Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 348. China Living Biological Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 349. China Living Biological Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 350. China Living Biological Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 351. India Living Biological Drugs Market Siz

Companies Mentioned

  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Novartis AG
  • Pfizer Inc.
  • Samsung Biologics Co.,Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals, Inc.
  • WuXi Biologics Co., Ltd.

Related Topics

Related Reports

Biological Drugs - Global Strategic Business Report - Product Image

Biological Drugs - Global Strategic Business Report

  • Report
  • 262 Pages
  • Global
From
Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 19-20, 2026) - Product Image

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 19-20, 2026)

  • Training
  • 2 Days
  • Global
Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 18-19, 2027) - Product Image

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (October 18-19, 2027)

  • Training
  • 2 Days
  • Global
Programmable Living Cell Therapeutics Market - Strategic Insights and Forecasts (2026-2031) - Product Image

Programmable Living Cell Therapeutics Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 165 Pages
  • Global
From
Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.